Oropharyngeal Cancer Treatment Pipeline Shows Strong Momentum as 10+ Pharma Companies in the Race | DelveInsight

DelveInsight’s, “Oropharyngeal Cancer Pipeline Insight 2026” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Oropharyngeal Cancer pipeline landscape. It covers the Oropharyngeal Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Oropharyngeal Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Oropharyngeal Cancer Pipeline @ https://www.delveinsight.com/sample-request/oropharyngeal-cancer-pipeline-insight

Key Takeaways from the Oropharyngeal Cancer Pipeline Report

• On February 27, 2026- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins conducted a NeoScorch HN study is a single institution multisite phase II trial including 3 cohorts of 25 patients each for patients with newly diagnosed locoregionally advanced, histologically confirmed, head and neck cancer eligible for curative-intent treatment, who will receive neo-adjuvant chemoimmunotherapy-based treatment as well as standard of care adjuvant treatment. The three cohorts include three different aspects of surgical de-escalation in head and neck cancer. The first cohort includes human papillomavirus independent (HPV-) squamous cell carcinoma of the head and neck.
• On February 27, 2026- Christian Hinrichs initiated a study is to determine the feasibility of administration of a single dose of E7 TCR-T cells as induction therapy prior to definitive treatment (chemoradiation or surgery) of locoregionally advanced HPV-associated cancers. The intent of E7 TCR-T cell treatment is to shrink or eliminate tumors and thereby facilitate definitive therapy and increase overall survival.
• On February 23, 2026- UNC Lineberger Comprehensive Cancer Center announced a study used a combination of chemotherapy consisting of carboplatin, paclitaxel and a third targeted anti-cancer drug. In this study the investigators are testing the combination of carboplatin, nano-albumin bound paclitaxel and durvalumab. Nano-albumin bound paclitaxel has been shown to be more active against other types of squamous cancers than regular paclitaxel. It is FDA approved for squamous lung cancer, but experimental for head and neck cancer. Durvalumab is an experimental drug that uses the body's own immune system to fight the cancer.
• On February 23, 2026- Merus B.V. conducted a Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma.
• DelveInsight’s Oropharyngeal Cancer pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Oropharyngeal Cancer treatment.
• The leading Oropharyngeal Cancer Companies such as AstraZeneca, ISA Pharmaceuticals, Pfizer, Bristol Myers Squibb, Advaxis, PDS Biotechnology, Debiopharm, Merck KGaA, Regeneron Pharmaceuticals/Sanofi and others.
• Promising Oropharyngeal Cancer Pipeline Therapies such as Paclitaxel, Carboplatin, Amifostine, Pembrolizumab, INBRX-106, Cevimeline hydrochloride, Cetuximab, Monalizumab, Petosemtamab, and others.

Stay ahead with the most recent pipeline outlook for Oropharyngeal Cancer. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Oropharyngeal Cancer Treatment Drugs

The Oropharyngeal Cancer Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Oropharyngeal Cancer Pipeline Report also highlights the unmet needs with respect to the Oropharyngeal Cancer.

Oropharyngeal Cancer Overview

Oropharyngeal Cancer is cancer in the oropharynx, which is the middle part of your throat (pharynx). The oropharynx includes the back one-third of the tongue, tonsils, soft palate and the side and back walls of the throat. Oropharyngeal Cancer is a type of head and neck cancer that accounts for about 18,000 newly diagnosed cases in the U.S. every year. Most oropharyngeal cancers are squamous cell carcinomas, meaning that the cancer is affecting your squamous cells, which are thin flat cells found in the lining of most of your organs. And although rare, lymphoma, or cancer affecting cells in the lymphatic system, can also occur at the base of the tongue and tonsils, which are made up of lymph tissue. Symptoms include a sore throat that doesn’t go away; a lump in the throat, mouth or neck; coughing up blood; white patch in the mouth and other symptoms.

Oropharyngeal Cancer Emerging Drugs Profile

• Cisplatin: AstraZeneca

Cisplatin works by stopping the cancer cells from multiplying. It does this by binding together the strands of the cells' genetic material, DNA. Cisplatin binds to the N7 reactive center on purine residues and as such can cause deoxyribonucleic acid (DNA) damage in cancer cells, blocking cell division and resulting in apoptotic cell death. The drug is being evaluated in Phase III clinical trials in combination with Durvalumab for the treatment of patients with Oropharyngeal cancer.

• ISA101B: ISA Pharmaceuticals

ISA101 consists of 12 synthetic long peptides (25 to 35 amino acids long) derived from the E6 and E7 oncogenic proteins of the HPV 16 virus, a strain responsible for over 50% of human cervical cancers and cervical intra-epithelial neoplasias, more than 85% of HPV-positive head and neck cancers, and similar substantial percentages of other premalignant and malignant HPV-induced lesions (such as VIN, vulvar cancer, AIN and anal cancer). It is currently administered either subcutaneously or intradermally. The drug is currently in Phase II stage of development for the treatment of patients with Oropharyngeal cancer.

Explore groundbreaking therapies and clinical trials in the Oropharyngeal Cancer Pipeline @ New Oropharyngeal Cancer Drugs

The Oropharyngeal Cancer Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Oropharyngeal Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Oropharyngeal Cancer Treatment.
• Oropharyngeal Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Oropharyngeal Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Oropharyngeal Cancer market

Oropharyngeal Cancer Companies

AstraZeneca, ISA Pharmaceuticals, Pfizer, Bristol Myers Squibb, Advaxis, PDS Biotechnology, Debiopharm, Merck KGaA, Regeneron Pharmaceuticals/Sanofi and others.

Oropharyngeal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
• Molecule Type

Oropharyngeal Cancer Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Unveil the future of Oropharyngeal Cancer Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Oropharyngeal Cancer Market Drivers and Barriers

Scope of the Oropharyngeal Cancer Pipeline Report

• Coverage- Global
• Oropharyngeal Cancer Companies- AstraZeneca, ISA Pharmaceuticals, Pfizer, Bristol Myers Squibb, Advaxis, PDS Biotechnology, Debiopharm, Merck KGaA, Regeneron Pharmaceuticals/Sanofi and others.
• Oropharyngeal Cancer Pipeline Therapies- Paclitaxel, Carboplatin, Amifostine, Pembrolizumab, INBRX-106, Cevimeline hydrochloride, Cetuximab, Monalizumab, Petosemtamab, and others.
• Oropharyngeal Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Oropharyngeal Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Oropharyngeal Cancer Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Oropharyngeal Cancer Companies, Key Products and Unmet Needs

Table of Contents

1. Introduction
2. Executive Summary
3. Oropharyngeal Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Oropharyngeal Cancer – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Oropharyngeal Cancer Collaboration Deals
9. Late Stage Products (Phase III)
10. Cisplatin: AstraZeneca
11. Mid Stage Products (Phase II)
12. ISA101B: ISA Pharmaceuticals
13. Early stage products (Phase I/II)
14. Genakumab: GeneScience Pharmaceuticals
15. Inactive Products
16. Oropharyngeal Cancer Key Companies
17. Oropharyngeal Cancer Key Products
18. Oropharyngeal Cancer- Unmet Needs
19. Oropharyngeal Cancer- Market Drivers and Barriers
20. Oropharyngeal Cancer- Future Perspectives and Conclusion
21. Oropharyngeal Cancer Analyst Views
22. Oropharyngeal Cancer Key Companies
23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/oropharyngeal-cancer-pipeline-insight

Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Oropharyngeal Cancer Treatment Pipeline Shows Strong Momentum as 10+ Pharma Companies in the Race | DelveInsight